Citadel Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-51,221
| Closed | -$309K | – | 10584 |
|
|
2019
Q4 | $309K | Sell |
51,221
-992,429
| -95% | -$5.74M | ﹤0.01% | 7540 |
|
|
2019
Q3 | $3.76M | Sell |
1,043,650
-1,079,698
| -51% | -$4.16M | ﹤0.01% | 3516 |
|
|
2019
Q2 | $5.69M | Sell |
2,123,348
-974,958
| -31% | -$2.88M | ﹤0.01% | 2915 |
|
|
2019
Q1 | $9.17M | Sell |
3,098,306
-2,388,788
| -44% | -$5.87M | ﹤0.01% | 2180 |
|
|
2018
Q4 | $8.72M | Buy |
5,487,094
+1,311,839
| +31% | +$3.71M | ﹤0.01% | 2067 |
|
|
2018
Q3 | $15.4M | Sell |
4,175,255
-504,569
| -11% | -$1.5M | 0.01% | 1639 |
|
|
2018
Q2 | $13.2M | Buy |
4,679,824
+1,805,261
| +63% | +$6.15M | 0.01% | 1664 |
|
|
2018
Q1 | $10.7M | Buy |
2,874,563
+2,139,919
| +291% | +$7M | 0.01% | 1663 |
|
|
2017
Q4 | $2.12M | Buy |
734,644
+633,626
| +627% | +$2.3M | ﹤0.01% | 3560 |
|
|
2017
Q3 | $453K | Sell |
101,018
-80,951
| -44% | -$359K | ﹤0.01% | 5474 |
|
|
2017
Q2 | $835K | Buy |
181,969
+25,767
| +16% | +$104K | ﹤0.01% | 4357 |
|
|
2017
Q1 | $658K | Sell |
156,202
-154,299
| -50% | -$641K | ﹤0.01% | 4608 |
|
|
2016
Q4 | $1.28M | Buy |
310,501
+18,425
| +6% | +$97.9K | ﹤0.01% | 3513 |
|
|
2016
Q3 | $2.37M | Buy |
292,076
+193,451
| +196% | +$1.64M | ﹤0.01% | 2772 |
|
|
2016
Q2 | $769K | Sell |
98,625
-245,462
| -71% | -$2.11M | ﹤0.01% | 3911 |
|
|
2016
Q1 | $2.66M | Sell |
344,087
-187,493
| -35% | -$1.37M | ﹤0.01% | 2369 |
|
|
2015
Q4 | $5.74M | Sell |
531,580
-140,246
| -21% | -$1.27M | 0.01% | 1690 |
|
|
2015
Q3 | $4.64M | Buy |
671,826
+511,736
| +320% | +$4.17M | ﹤0.01% | 2017 |
|
|
2015
Q2 | $1.42M | Buy |
160,090
+98,965
| +162% | +$936K | ﹤0.01% | 3496 |
|
|
2015
Q1 | $602K | Buy |
61,125
+9,337
| +18% | +$117K | ﹤0.01% | 4642 |
|
|
2014
Q4 | $635K | Sell |
51,788
-459,940
| -90% | -$5.62M | ﹤0.01% | 4373 |
|
|
2014
Q3 | $5.11M | Buy |
511,728
+357,052
| +231% | +$3.31M | 0.01% | 1967 |
|
|
2014
Q2 | $1.17M | Buy |
154,676
+138,513
| +857% | +$553K | ﹤0.01% | 3302 |
|
|
2014
Q1 | $53K | Sell |
16,163
-45,053
| -74% | -$158K | ﹤0.01% | 6746 |
|
|
2013
Q4 | $203K | Sell |
61,216
-117,940
| -66% | -$342K | ﹤0.01% | 5012 |
|
|
2013
Q3 | $541K | Buy |
179,156
+110,497
| +161% | +$757K | ﹤0.01% | 3727 |
|
|
2013
Q2 | $561K | Buy |
+68,659
| New | +$524K | ﹤0.01% | 3720 |
|
Citadel Advisors's ACHN Position: Q1 2020 in Review
Citadel Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 51,221 shares — an estimated $309K sold.
Citadel Advisors first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $15.4M in Q3 2018. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Citadel Advisors reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Citadel Advisors sold 51,221 Achillion Pharmaceuticals shares in Q1 2020, an estimated $309K.
- Citadel Advisors first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Citadel Advisors's Achillion Pharmaceuticals position peaked at $15.4M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.